Medicus Pharma Ltd. has 6 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Melani Kenneth R. | 18.2% | 3,248,741 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| Bokhari, Raza | 5.3% | 4,859,349 | SCHEDULE 13D, 2026-09-14 | 2026-09-04 |
| Armistice Capital, LLC | 4.99% | 935,724 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| John Hathaway | 4.5% | 800,952 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| Raju Ajay | 3.7% | 2,031,250 | SCHEDULE 13G/A, 2026-05-05 | 2026-03-31 |
Purpose of Transaction (Item 4)
Bokhari, Raza
The Reporting Persons hold the securities reported herein for investment purposes and in the capacities further described below. Dr. Bokhari acquired, and holds, such securities both directly, and through his control of RBx Capital, LP, as applicable, in connection with his service as Executive Chairman and Chief Executive Officer of the Issuer, and as an initial investor in the securities of the Issuer at the time of its reverse take-over transaction as described in the Issuer's filings with the Commission. In his capacity as Executive Chairman and Chief Executive Officer of the Issuer, Dr. Bokhari participates in the management and direction of the business and affairs of the Issuer and, in that capacity, regularly considers, formulates and discusses with other members of management and with the board of directors of the Issuer, and votes upon as a director, matters relating to the Issuer's business, operations, strategy, capitalization, financing arrangements, dividend policy, board and management composition, corporate structure and strategic alternatives, including matters of the types described in clauses (a) through (j) of Item 4 of Schedule 13D. Dr. Bokhari may take such actions in his capacity as an officer and director of the Issuer, in each case subject to his fiduciary duties to the Issuer and its shareholders. Each Reporting Person intends to review its investment in the Issuer on a continuing basis and, depending upon various factors, including the Issuer's …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | John Hathaway | 4.5% | SCHEDULE 13G/A |
| 2025-08-12 | Melani Kenneth R. | 18.2% | SCHEDULE 13G/A |
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-01-05 | Bokhari Raza | 4.8% | SCHEDULE 13G/A |
| 2026-05-05 | Raju Ajay | 3.7% | SCHEDULE 13G/A |
| 2026-09-14 | Bokhari, Raza | 5.3% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Medicus Pharma Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.